rs3733590 — SLC2A9

SLC2A9 rs3733590 — An East Asian-Enriched Intronic Tag Variant at the Major Urate Locus

Your serum uric acid level is regulated more by your genes than most people realize, and the single most powerful genetic locus for that regulation is the SLC2A9 gene on chromosome 4. SLC2A9 encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, a high-capacity urate transporter in the renal proximal tubule that mediates urate reabsorption back into the bloodstream — despite its name, it transports urate far more efficiently than glucose. Variants throughout this gene, both coding and intronic, collectively explain more of the variance in serum uric acid than any other locus in the human genome.

rs3733590 is an intronic variant within SLC2A9, positioned at chromosome 4:9,985,602 (GRCh38). It does not change the GLUT9 protein sequence, but RNA sequencing evidence has identified that this variant modifies a cryptic intronic donor splice site, potentially influencing how the SLC2A9 transcript is processed. Its most striking feature is its allele frequency distribution: the C allele is found in roughly 41% of East Asian individuals, compared to only 5% of Europeans and approximately 14% of Africans. This pattern closely mirrors the population distribution of serum uric acid levels and gout prevalence globally, suggesting the variant either directly influences urate transport efficiency or marks a broader risk haplotype at this locus.

The Mechanism

rs3733590 is located within an intron of SLC2A9 — it does not alter the GLUT9 amino acid sequence. Its putative functional relevance rests on two lines of evidence. First, the C allele's striking population frequency gradient (East Asian 41%, African 14%, European 5%) mirrors other SLC2A9 intronic tag SNPs that mark the urate-raising haplotype block. Across population genetics studies, East Asian populations show elevated serum uric acid and higher gout prevalence, and several SLC2A9 intronic variants track this distribution.

Second, ClinVar (VCV001275932) cites RNA sequencing evidence that this intronic position influences a cryptic splice donor site, with statistically significant exon-skipping effects (p = 0.0001). If the C allele disrupts normal SLC2A9 pre-mRNA splicing, this could alter the ratio of the two functionally distinct GLUT9 isoforms — the long isoform (GLUT9a, basolateral, mediating reabsorption from the interstitium) and the short isoform (GLUT9b, apical). A shift in isoform balance would change net renal urate handling without altering the protein sequence of either isoform.

This mechanism — intronic variant affecting splice site efficiency — is increasingly recognized as a common molecular mechanism for GWAS tag SNPs that previously appeared to have no obvious functional consequence.

The Evidence

The SLC2A9 locus and serum uric acid: SLC2A9 was independently identified as the dominant genetic determinant of serum uric acid in two landmark 2008 studies. Vitart et al.²² Vitart et al. identified intronic SLC2A9 variants explaining 1.7–5.3% of serum urate variance in Croatian and UK/German cohorts — the largest single-locus effect reported in urate genetics. Döring et al.³³ Döring et al. reported a striking sex-specific effect: the SLC2A9 intronic signal explains 6% of urate variance in women but only 1.2% in men, attributed to an interaction with estrogen, which independently stimulates renal urate excretion.

Population frequency as indirect evidence: The C allele frequency at rs3733590 — 41% in East Asians, 5% in Europeans — tracks the population gradient of serum urate and gout prevalence. East Asian populations consistently show higher SLC2A9-locus risk allele frequencies for intronic tag SNPs that associate with urate elevation, even when those tag SNPs have not been individually genotyped in every GWAS study. This frequency pattern constitutes indirect epidemiological evidence that the C allele at rs3733590 marks a risk haplotype at this locus, though direct per-SNP association statistics for rs3733590 specifically are not available in the published literature.

Splicing evidence: Clinical RNA sequencing data submitted to ClinVar (VCV001275932) identified exon skipping attributable to this variant (p = 0.0001), providing molecular plausibility for a regulatory mechanism. The variant was classified "Benign" by two clinical lab submitters in the context of rare disease evaluation, reflecting the absence of pathogenic Mendelian disease associations rather than a judgment about quantitative trait influence.

Relationship to established SLC2A9 signals: This variant is adjacent in genomic space (within 25 kb) to rs3733591 (Arg265His, a functional missense variant) and rs11942223 (a well-characterised intronic signal). The relationship with rs3733585 (also SLC2A9 intronic) has not been formally characterized in the published literature; linkage disequilibrium measurements between rs3733590 and these neighboring variants are not publicly reported in the studies identified for this profile. Whether rs3733590 tags an independent signal or is in LD with an established lead SNP requires conditional analysis not yet available.

Practical Actions

Given the emerging evidence level, the primary implication of carrying the C allele at rs3733590 is context-dependent risk awareness rather than an immediate clinical mandate. The variant's allele frequency gradient is consistent with tagging the SLC2A9 risk haplotype, and the splicing mechanism provides biological plausibility. Practically, the same urate-management levers that apply to established SLC2A9 variants remain relevant: reducing dietary purine load, limiting fructose-sweetened beverages (which raise urate via hepatic metabolism and compete with urate for renal excretion), and monitoring serum uric acid if other risk factors are present.

The absence of direct GWAS evidence for rs3733590 itself means the effect size is uncertain. The most conservative reading is that C allele carriers should check the established SLC2A9 variants (rs3733591, rs11942223) for their primary urate genetic risk, and treat rs3733590 as an additional signal warranting awareness rather than standalone clinical intervention.

Interactions

With rs3733591 (SLC2A9 Arg265His): rs3733591 is the functional coding variant at this locus, with each C allele adding approximately 0.65 mg/dL to serum uric acid. The relationship between rs3733590 and rs3733591 in terms of LD has not been formally characterized, but given their proximity and similar East Asian frequency enrichment, they may partially co-tag the same risk haplotype. Individuals carrying C alleles at both variants should be assessed as carrying compounded SLC2A9 risk.

With rs11942223 (SLC2A9 intronic, independent signal): rs11942223 tags a second independent intronic signal at SLC2A9 with proven sex-specific effects (explaining 6% of urate variance in women). This signal is confirmed independent of rs3733591. The independence of rs3733590 from rs11942223 has not been formally tested.

With ABCG2 rs2231142 (Q141K): ABCG2 reduces intestinal urate secretion through an entirely different pathway. Risk alleles at SLC2A9 (renal reabsorption) and ABCG2 (gut secretion) act additively to raise serum urate. Individuals carrying C alleles at rs3733590 alongside T alleles at ABCG2 rs2231142 carry compounded risk from two urate-regulating systems.

Sex and menopausal status: The broader SLC2A9 intronic signal is substantially larger in women (up to 6× the variance explained vs men), attributed to estrogen's independent uricosuric action. Post-menopausal women who carry C alleles at rs3733590 lose this hormonal buffer and may be the highest-risk subgroup.